Tech Center 1600 • Art Units: 1616 1636
This examiner grants 47% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18553774 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | Non-Final OA | Merck Sharp & Dohme LLC |
| 17822746 | EFFICIENT GENOME EDITING IN PRIMARY MYELOID CELLS | Non-Final OA | Genentech, Inc. |
| 17820005 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | Non-Final OA | NOVARTIS AG |
| 19245028 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | Final Rejection | BASECURE THERAPEUTICS LLC |
| 17950573 | PRUSSIAN BLUE NANOPARTICLES FUNCTIONALIZATION WITH LATENCY REVERSING AGENTS AND BROADLY NEUTRALIZING ANTIBODIES, AND APPLICATIONS THEREOF | Final Rejection | THE GEORGE WASHINGTON UNIVERSITY |
| 18273501 | CRISPR-ASSOCIATED BASED-EDITING OF THE COMPLEMENTARY STRAND | Non-Final OA | Wageningen Universiteit |
| 17791504 | LONG-ACTING THERAPEUTIC AGENT COMBINATIONS AND METHODS THEREOF | Non-Final OA | University of Washington |
| 17710783 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS B VIRUS INFECTION | Final Rejection | University of Washington |
| 18556614 | ALL-IN-ONE DENDRIMER-BASED LIPID NANOPARTICLES ENABLE PRECISE HDR-MEDIATED GENE EDITING IN VIVO | Non-Final OA | The Board of Regents of The University of Texas System |
| 18335990 | LIPOCATIONIC DENDRIMERS AND USES THEREOF | Non-Final OA | The Board of Regents of The University of Texas System |
| 17626674 | MULTILAMELLAR RNA NANOPARTICLES | Final Rejection | University of Florida Research Foundation, Inc. |
| 18248988 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | Non-Final OA | SANOFI |
| 17501635 | UNIVERSAL MULTI-FUNCTIONAL GSH-RESPONSIVE SILICA NANOPARTICLES FOR DELIVERY OF BIOMOLECULES INTO CELLS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17787089 | SYNTHETIC PROCESSES AND INTERMEDIATES | Non-Final OA | ARBUTUS BIOPHARMA CORPORATION |
| 17906134 | COMPOSITIONS AND METHODS COMPRISING IMPROVED GUIDE RNAs | Non-Final OA | Cornell University |
| 17641741 | CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF | Final Rejection | DAIICHI SANKYO COMPANY, LIMITED |
| 18130761 | CONTACT LENS PRODUCT WITH CORNEA REPAIR FUNCTION | Non-Final OA | PEGAVISION CORPORATION |
| 18427072 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17736251 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17774477 | EXTRAHEPATIC DELIVERY | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17668917 | ENDOSOMAL CLEAVABLE LINKERS | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 18001571 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | Non-Final OA | Arcturus Therapeutics, Inc. |
| 17432237 | COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION | Final Rejection | Ionis Pharmaceuticals, Inc. |
| 18218166 | Horticulture Additive | Final Rejection | Milliken & Company |
| 18028751 | PATIENT SELECTION BIOMARKERS FOR TREATMENT WITH ULK INHIBITORS | Non-Final OA | Salk Institute for Biological Studies |
| 17754196 | OLIGONUCLEOTIDE, AND TARGET RNA SITE-SPECIFIC EDITING METHOD | Non-Final OA | Fukuoka University |
| 18032663 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | Non-Final OA | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED |
| 17766318 | Targeted Nanomedicine for Treating Vascular Disorders | Non-Final OA | THE UNIVERSITY OF UTAH |
| 17570498 | BIO-DEGRADABLE MICROCAPSULES | Final Rejection | INTERNATIONAL FLAVORS & FRAGRANCES INC. |
| 18274496 | SYNERGISTIC EFFECT OF SMN1 AND MIR-23A IN TREATING SPINAL MUSCULAR ATROPHY | Non-Final OA | JOINT STOCK COMPANY «BIOCAD» |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy